- Open Access
The impact of the novel coronavirus disease (COVID-19) pandemic on drug overdose-related deaths in the United States and Canada: a systematic review of observational studies and analysis of public health surveillance data
Substance Abuse Treatment, Prevention, and Policy volume 16, Article number: 87 (2021)
There are preliminary indications that the trajectory of drug overdose-related deaths in North America has been exacerbated due to the novel coronavirus disease pandemic (COVID-19). As such, the impact of COVID-19 on drug overdose-related deaths was examined through a systematic review of the literature and percentage change analyses of surveillance data.
Systematic searches in electronic databases were conducted, a topical issue brief and bibliography were reviewed, reference lists of included studies were searched and expert consultations were held to identify studies (Registration # CRD42021230223). Observational studies from the United States and Canada were eligible for inclusion if drug overdose-related deaths were assessed in quantitative or qualitative analyses onwards from at least March 2020. In addition, percentage changes comparing drug overdose-related deaths in the second annual quarter (Q2 2020 [April to June]) with the first annual quarter (Q1 2020 [January to March]) were generated using national and subnational data from public health surveillance systems and reports from jurisdictions in the United States and Canada.
Nine studies were included in the systematic review, eight from the United States and one from Canada. The maximum outcome assessment period in the included studies extended until September 2020. Drug overdose-related deaths after the onset of COVID-19 were higher compared with the months leading up to the pandemic in 2020 and the comparative months in 2019. In additional percentage change analyses, drug overdose-related deaths increased by 2 to 60% in jurisdictions in the United States and by 58% in Canada when comparing Q2 2020 with Q1 2020.
Drug overdose-related deaths increased after the onset of COVID-19. The current situation necessitates a multi-pronged approach, encompassing expanded access to substance use disorder treatment, undisrupted access to harm reduction services, emphasis on risk reduction strategies, provision of a safe drug supply and decriminalization of drug use.
The severe acute respiratory syndrome coronavirus (SARS-CoV-2) is a zoonotic coronavirus, the causative agent of the novel coronavirus disease (COVID-19) . Given the severity of the outbreaks across the globe, the World Health Organization declared it a pandemic on March 11, 2020. More than 119 million confirmed cases and 2.6 million deaths have been documented as of March 15, 2021, with about 28% of them occurring within North America . In response to the rising burden of disease, government authorities have implemented public health measures to reduce the contact rate, such as physical distancing restrictions, closures of non-essential services, working from home and limitations on public gatherings and events . Self-isolation after potential exposure or symptom development has been recommended or mandated depending on the local jurisdiction. Despite their utility in reducing the spread of the disease, these measures are associated with substantial social and economic consequences [3, 4], with disproportionate impacts on marginalized populations, including people who use drugs (PWUD).
Prior to the declaration of the pandemic in March 2020, the United States and Canada were in the midst of a drug overdose crisis [5, 6], which has worsened since the onset of COVID-19. “Big events” – major disruptions that create social instability (e.g. natural disasters, financial crises and heroin shortages) – disrupt drug market dynamics, resulting in changes to the availability, accessibility, price and potency of drugs, ultimately leading to the switching of drugs and alteration of consumption habits among PWUD . Indeed, increases in the price and adulteration of drugs and decreases in the availability of drugs have been documented since the onset of COVID-19 , with subsequent engagement in riskier behaviors (e.g. sharing paraphernalia) by PWUD . Simultaneous to the changes in drug market dynamics, there have been interruptions in the delivery of harm reduction and addiction treatment services due to COVID-19 . Experiences of detrimental access and disrupted treatment have been documented for a range of services among PWUD, including supervised consumption services, needle exchange programs, mobile outreach programs, withdrawal management services and opioid agonist treatment . Importantly, physical distancing restrictions intended to reduce the transmission of COVID-19 have resulted in drug usage alone by PWUD, limiting the opportunity of others to respond in an event of a drug overdose . Therefore, the risk of drug overdose-related deaths is magnified.
Syndromic surveillance lends support to these findings [11, 12]. Based on the Centers for Disease Control and Prevention’s National Syndromic Surveillance Program in the United States, rates of emergency visits for drug overdoses and opioid overdoses decreased after the initial implementation of the public health measures, but subsequently rebounded starting at the end of March 2020 . Importantly, median emergency visits for drug overdoses and opioid overdoses were higher between March 2020 to October 2020 compared with between March 2019 to October 2019 . A similar pattern is also emerging for drug overdose-related deaths, as two rapid reviews conducted during the early stages of the pandemic suggest increases in drug overdose-related deaths in Canada [13, 14]. However, given the absence of national, real-time mortality statistics, the full extent of the impact of COVID-19 on drug overdose-related deaths remains to be characterized. Reports from multiple jurisdictions can be triangulated to inform interventions and policies in the interim. Accordingly, the present objectives were as follows:
Review observational studies that examined the impacts of COVID-19 on drug overdose-related deaths in the United States and Canada.
Quantify percentage changes in drug overdose-related deaths before and after the onset of COVID-19 based on public health surveillance systems and reports from the United States and Canada.
Drug overdose-related death case definition
Drug overdose-related deaths hereunder were operationalized as drug poisoning deaths attributable to, but not limited to, opioids, cocaine and amphetamines, which encompassed different types of drugs (pharmaceutical, non-pharmaceutical [i.e. illegal]), places of death (residence, public place, unknown) and manners of death (unintentional, intentional, undetermined), as available.
The reporting of the systematic review was consistent with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Guidelines (Prospero Protocol Registration: CRD42021230223; See reporting checklist in Table S1 in Additional File 1) . Electronic searches were conducted in Medline, Embase and PsycInfo to identify studies published from database inception to December 18, 2020 (see Additional File 1 for the search strategies). In order to be as comprehensive as possible, and to reduce the risk of publication bias, additional sources were drawn upon to identify studies:  keyword searches in Google Scholar were conducted , an issue brief listing reports of drug overdose-related deaths in the United States was reviewed ,  a bibliography of published studies on addiction-related topics and COVID-19 was assessed ,  reference lists of included studies were examined and  expert consultations were held . The titles and abstracts were reviewed in the first round of screening, and the full texts were reviewed in the second round of screening. The selection criteria were as follows:
Assessments incorporating data onwards from at least March 2020 (considered to be the onset of COVID-19).
United States, Canada or Mexico as locations. However, as no studies were found that originated from Mexico, the protocol was modified to include United States and Canada as locations.
Drug overdose-related deaths as an outcome.
Quantitative or qualitative analyses.
No language restrictions were applied, and unpublished literature was eligible for inclusion. Unpublished literature was included to capture all available evidence, as peer-reviewed manuscripts were expected to be limited in number due the timeliness of the topic. Prior reviews, animal studies, newspaper articles and opinion pieces (i.e. lacking empirical data; e.g. commentaries and research letters) were excluded. Similarly, routine public health surveillance reports were excluded (e.g. ), as they tended to include statistics on drug overdose-related deaths rather than quantify the impacts of COVID-19 on drug overdose-related deaths. However, data from them were extracted for the Percentage Change Analyses. Studies that met the selection criteria proceeded to the data extraction, where details on location, time period, population, outcome definition and ascertainment and main findings were noted. Risk of bias assessments were not conducted, as most studies were published as government documents or independent research reports.
Two authors (SI and JR) developed the electronic search strategies, which included keywords from the conceptual domains of mortality, drugs and COVID-19 (detailed search strategies for all databases are available in Additional File 1). Two authors (SI and FN) executed the electronic search strategies, screened titles and abstracts and reviewed the full texts. Disagreements between the two authors in the selection of studies were resolved by consultation with a third author (JR). One author (SI) completed the data extraction, with subsequent review and verification by another author (FN). Multiple reports from included studies were considered in the data abstraction.
As the outcome definitions were expected to vary considerably between the included studies, findings were not pooled quantitatively in a meta-analysis, rather findings were synthesized qualitatively in a narrative synthesis. The findings were grouped and reported according to two comparison periods for drug overdose-related deaths after the onset of COVID-19: 1) months leading up to the pandemic in 2020 (e.g. March to April 2020 vs. January to February 2020); and 2) comparative months from 2019 (e.g. March to June 2020 vs. March to June 2019). Percentage changes in drug overdose-related deaths from these studies were summarized as range of effects and directionality of effects (through vote counting). Findings from all pertinent analyses were additionally presented, as available.
Percentage change analyses
Data from national or subnational (state and provincial) government public health surveillance systems and reports were compiled through electronic searches of Google (using keywords such as “drug deaths”. “opioid deaths” and “overdose deaths”), review of a listing of opioid dashboards and data assembled by the Carolina Center for Health Informatics  and expert consultations (with membership of the Canadian Research Initiative on Substance Misuse). These electronic searches for the percentage change analyses were not systematic, although a similar set of keywords were utilized. To be eligible for data extraction and analysis, data had to be available according to or be amenable to formatting as annual quarters (Quarter 1 [Q1]: January to March; Q2: April to June; Q3: July to September; Q4: October to December) minimally from January 2020 to June 2020. No exclusions were made on the basis of other criteria, including current reporting status (preliminary, finalized).
Data pertaining to the broadest available category of drug overdose-related deaths were extracted until Q3 2020. For example, drug overdose-related deaths were extracted rather than opioid overdose-related deaths, fentanyl overdose-related deaths or psychostimulant overdose-related deaths, if data on all four were available. If such a broad category of drug overdose-related deaths was not available, data pertaining to opioid overdose-related deaths were extracted, as they represent the main driver of drug overdose-related deaths in most jurisdictions in North America. Subnational data were extracted for 12 jurisdictions in the United States (Connecticut, Indiana, Louisiana, Maine, Massachusetts, Mississippi, New Hampshire, New Jersey, Rhode Island, Vermont, Virginia, Washington) and national data were extracted for Canada. However, as the national data were available until Q2 2020 in Canada, additional subnational data that extended until Q3 2020 were extracted from Alberta, British Columbia and Quebec. The primary analysis included computation of percentage changes in drug overdose-related deaths comparing Q2 2020 with Q1 2020 separately for all jurisdictions. The secondary analyses included: 1) computation of analogous percentage changes comparing the subsequent quarters to characterize the trajectory of the impact of COVID-19; and 2) computation of analogous percentage changes comparing quarters from 2020 with quarters from 2019 to contextualize the impact of COVID-19.
All research activities were conducted as part of the Ontario Node of the Canadian Research Initiative on Substance Misuse Project. No additional review and approval was required, as aggregated data were extracted from publicly available studies and public health surveillance systems and reports.
Characteristics of included studies
After the application of the selection criteria, nine studies from 419 unique studies were included in the systematic review, all of them published in English (Fig. 1) [21,22,23,24,25,26,27,28,29]. Four included studies were published as government documents, three included studies were published as peer-reviewed manuscripts and two included studies were published as independent research reports.
The characteristics of all included studies are detailed in Table 1. Eight included studies were from the United States (Georgia, Kentucky, Michigan, Minnesota, Marion County [Indiana] and San Francisco [California]) and one included study was from Canada (Ontario). Although the maximum outcome assessment period in the included studies extended until September 2020, most included studies’ outcome assessment period did not extend past June 2020. The data sources for procuring the drug overdose-related deaths varied in the included studies, including emergency medical services systems, offices of the chief medical officer or coroner, vital records systems and other electronic surveillance systems. In a similar manner, the operationalization of drug overdose-related deaths in the included studies varied as well, with four of the nine included studies focusing exclusively on opioids.
The findings from all included studies are detailed in Table 1. Descriptive analyses (percentage changes and computations of deaths per day or month) represented the analytical strategies in all included studies, with autoregressive integrated moving average forecasting models additionally utilized in one included study. The findings are summarized hereunder for the broadest available category of drug overdose-related deaths after the onset of COVID-19 according to two comparison periods: 1) months leading up to the pandemic in 2020; and 2) comparative months in 2019.
In comparison to the months leading up to the pandemic in 2020, drug overdose-related deaths after the onset of COVID-19 were higher in seven studies [21,22,23, 26,27,28,29]. Drug overdose-related deaths were 9 to 50% higher between the periods of March 2020 to July 2020 compared with between the periods of December 2019 to March 2020 as observed in Georgia, Kentucky, Minnesota and Marion County [21, 23, 27, 28]. Opioid overdose-related deaths rose from 0.95 deaths per day between January 01, 2020 and March 15, 2020 to 1.47 deaths per day between March 16, 2020 and April 18, 2020 in San Francisco, representing a percentage increase of 55% . Based on records received and processed at the time of analysis, drug overdose-related deaths in the 12-months ending in May 2020 were 18% higher compared with in the 12-months ending in June 2019 in the United States . Importantly, the average increase per month in drug overdose-related deaths amounted to 2348 deaths after the onset of COVID-19 (12-months ending in March 2020 to 12-months ending in May 2020) compared with 680 deaths before the onset of COVID-19 (12-months ending in June 2019 to 12-months ending in February 2020) nationally in the United States . Opioid overdose-related deaths in Ontario increased by 38% between March 16, 2020 and June 30, 2020 compared with between December 01, 2019 and March 15, 2020 .
In comparison with the comparative months in 2019, drug overdose-related deaths after the onset of COVID-19 were higher in five studies [22,23,24,25, 28]. Drug overdose-related deaths were 15, 40 and 104% higher between the periods of March 2020 to September 2020 compared with between the periods of March 2019 to September 2019, as observed in Michigan, Minnesota and Marion County, respectively [23, 24, 28]. Opioid overdose-related deaths were higher in January, February, March and April of 2020 compared with January, February, March and April of 2019 (6, 18, 15, 13 deaths per month vs. 27, 34, 35, 25 deaths per month, respectively) in San Francisco . Based on agencies participating in the Overdose Detection Mapping Application Program System throughout the United States, rolling average of drug overdose-related deaths in the past 30 days were 11% higher between January and May 2020 compared with between January and December 2019 .
Percentage change analysis
The findings from the percentage change analyses are presented in Table 2 (see Additional Files 2 and 3 for data sources, derivation notes and death counts). Jurisdictions in the United States reported variations of either drug overdose-related deaths or opioid overdose-related deaths. Drug overdose-related deaths increased by 2 to 60% in Q2 2020 compared with Q1 2020 in jurisdictions in the United States. Variations of either opioid overdose-related deaths or illicit drug overdose-related deaths were reported in jurisdictions in Canada. Drug overdose-related deaths increased 58% in Q2 2020 compared with Q1 2020 in Canada. During the same time period, drug overdose-related deaths more specifically increased 107% in Alberta, 80% in British Columbia and 28% in Quebec. Among jurisdictions that reported drug overdose-related deaths in Q3 2020, comparisons with Q2 2020 demonstrated increases in two jurisdictions in the United States and two jurisdictions in Canada (3 to 6% and 12 to 13%, respectively), and decreases in four jurisdictions in the United States and one jurisdiction in Canada (− 6% to − 30% and − 2%, respectively). On the other hand, drug overdose-related deaths in Q1 2020 compared with Q1 2019 demonstrated increases in all jurisdictions in the United States (1 to 72%), with the exception of Mississippi and New Hampshire. Decreases were evident in this regard in all examined jurisdictions in Canada (− 3% to − 9%). However, drug overdose-related deaths from Q1-Q2 2020 compared with Q1-Q2 2019 demonstrated increases in all but one jurisdiction in the United States and Canada (4 to 50%). This pattern of finding persisted when comparing Q1-Q3 2020 with Q1-Q3 2019 (2 to 62%).
Summary of findings
Observational studies that examined the impact of COVID-19 on drug overdose-related deaths in the United States and Canada were reviewed. Drug overdose-related deaths after the onset of COVID-19 were higher compared with the months leading up to the pandemic in 2020 or comparative months in 2019. In additional percentage change analyses based on data from public health surveillance systems and reports, drug overdose-related deaths increased by 2 to 60% in jurisdictions in the United States and by 58% in Canada between Q1 2020 and Q2 2020. These findings indicate that drug overdose-related deaths increased after the onset of COVID-19.
Comparison with previous studies
Two rapid reviews have examined the impact of COVID-19 on drug overdose-related deaths based on empirical evidence [13, 14]. As they were both conducted during the early stages of COVID-19, there is minimal overlap with the studies or the public health surveillance systems data included hereunder [13, 14]. Largely on the basis of public health surveillance systems in Canada, increases in drug overdose-related deaths in British Columbia and Ontario (including Toronto and Simcoe Muskoka District Health Unit) were highlighted [13, 14]. However, it was difficult to conclude whether the increases were attributable to the toxic drug supply, COVID-19 or a combination of both [13, 14]. In a subsequent assessment from Philadelphia that was published after the completion of the systematic searches, Khatri and colleagues demonstrated increases in opioid overdose-related deaths between April 2020 and June 2020 compared with between December 2019 and February 2020 among non-Hispanic Blacks (mean monthly overdose deaths of 49 deaths vs. 30 deaths; p = 0.04), but not among non-Hispanic Whites (35 deaths vs. 45 deaths; p = 0.11) or Hispanics (14 deaths vs. 13 deaths; p = 0.57) .
Interpretation and implications
Drug overdose-related deaths increased prior to and accelerated after the onset of COVID-19 in the United States. In contrast, drug overdose-related deaths stabilized prior to the onset of COVID-19, but increased after the onset of COVID-19 in Canada. Although seasonal variations (e.g. due to weather and holidays) may have contributed to some extent to the increase in drug overdose-related deaths, they probably do not explain the entirety of the findings. The percentage change in drug overdose-related deaths between Q1 and Q2 was 3% (mean; range − 40 to 38%) in 2019 and 21% (mean; range 2 to 60%) in 2020 in jurisdictions in the United States and − 4% in 2019 and 58% in 2020 in Canada, which suggests the potential role of the consequences of COVID-19. However, given the absence of studies with stronger methodological designs (e.g. interrupted time series design and regression discontinuity design), it is difficult to draw causal inferences because the impact of other factors cannot be ruled out. As such, these conclusions are preliminary that require further confirmation in future research.
Despite the preliminary nature of the current state of the evidence, it is clear that the rise in drug overdose-related deaths after the onset of COVID-19 necessitates actions on five fronts. The applicability of these recommendations will vary depending on local jurisdiction laws. First, expanded access to substance use disorder treatment needs to be facilitated, especially the delivery of services through innovative models of care to ensure minimal disruptions in treatment. Notably, telemedicine has facilitated low-barrier access to opioid pharmacotherapy with buprenorphine in the United States, as the federal regulatory changes enacted during the pandemic now permit clinicians to prescribe buprenorphine after conducting an initial visit using audio-visual or telephonic assessments rather than in-person assessments . Removal of the in-person assessment requirement has resulted in rapid initiation of treatment, often including same day assessments, prescriptions and inductions [31, 32]. In addition, given the recent rise in psychostimulant overdose-related deaths [33, 34], treatment options for both opioid use disorder and psychostimulant use disorder are needed. Second, undisrupted access to harm reduction services needs to be ensured, including drug checking programs that make use of a wide range of technologies (e.g. fourier-transform infrared (FTIR) spectrometers, fentanyl test strips and drug testing kits), needle and syringe exchange programs and supervised consumption services, all of which have demonstrated varied range of benefits in terms of injecting risk behaviors, bloodborne infectious diseases and drug overdoses [35,36,37]. Third, drug overdose prevention needs to emphasize risk reduction strategies during episodes of drug consumption: not to use drugs alone, determine the contents of drugs beforehand, ensure availability of naloxone on-hand and have someone check-in during consumption . In particular, novel strategies such as virtual drug use spotting through social networks (e.g. phone calls, video calls) or technological innovations (e.g. smart phone applications) can be drawn upon when using drugs alone, an intervention where substances are consumed under observation and emergency services are alerted in the event of unresponsiveness [38, 39]. Wider availability of naloxone is similarly imperative in the current context, which has been shown to increase drug overdose emergency visits and decrease drug overdose deaths . Fourth, to reduce drug use attributable risks and harms due to the toxic drug supply in North America, access needs to be provided to a safe drug supply (defined as legal and regulated supply of psychoactive substances that are typically available from the illegal drug market) [41, 42]. Fifth, the unprecedented circumstances suggest that there is a need for decriminalization of drug use, which will prioritize health over punishment, reduce stigma surrounding drug use and enable earlier engagement with prevention and treatment interventions [41, 43, 44]. Importantly, although these recommendations were relevant prior to the onset of COVID-19, their expedited, large-scale adoption is now high-priority given the rise in drug overdose-related deaths. In addition to these specific recommendations to address drug overdose-related deaths, prioritized access to vaccinations needs to be ensured for PWUD , who have intersecting social and health vulnerabilities that may elevate the risk for the infection, complications and mortality due to COVID-19 [46,47,48]. PWUD experience homelessness and incarceration, high prevalence of pre-existing chronic health conditions, inadequate access to shelters and barriers to harm reduction services [8, 10, 49,50,51]. In addition, substance use characteristics such as sharing paraphernalia and inability to social distance or self-isolate may further amplify the risks due to COVID-19 . As such, access to vaccination is a priority for this population, which can be facilitated through the existing physical infrastructure of harm reduction and addiction treatment services .
There are some limitations that should be considered in the interpretation of the findings. First, non-fatal drug overdoses were not considered in the systematic review or percentage change analyses. As such, the full extent of the impact of COVID-19 on drug overdoses is probably larger. Second, despite the broad search strategies and expert consultations, studies from Canada were not well represented and studies from Mexico were not found in the systematic review, limiting the generalizability of the findings. In a similar manner, as the percentage change analyses included 12 jurisdictions from its states and territories, the findings may not be generalizable to the rest of the United States. Third, given the heterogenous definitions of drug overdose-related deaths in the included studies in the systematic review, quantitative synthesis of the findings through meta-analysis was not possible. Fourth, due to the need for timely evidence in the context of a rapidly escalating health crisis, data in some of the included studies in the systematic review were preliminary and subject to change, based on health surveillance systems or health administrative databases that are susceptible to misclassification bias and lacked confirmation through toxicological analyses or physician diagnoses. On that same note, data from all jurisdictions in the percentage change analyses were preliminary and subject to change. The onset of COVID-19 in particular has underscored the urgent need for standardized, real-time statistics on drug overdose-related deaths, as they are not available consistently across jurisdictions in North America. These limitations concerning the outcome assessment may have impacted the validity of the findings. Fifth, outcome assessment period in the included studies in the systematic review or percentage change analyses did not extend past September 2020, warranting a need for continued monitoring of drug overdose-related deaths. Sixth, stronger methodological designs were absent from most studies, and descriptive analyses (without statistical tests of differences) represented the analytical strategy in all but one of the included studies in the systematic review. Percentage change analyses were operationalized hereunder, as the granular data required for interventional time series analyses were not publicly available.
Drug overdose-related deaths after the onset of COVID-19 were higher compared with the months leading up to the pandemic in 2020 or comparative months in 2019 in the United States and Canada. Similar increases were reflected in percentage change analyses of drug overdose-related deaths comparing Q2 2020 with Q1 2020. Although these findings are widespread, further confirmation is needed, as the impact of other factors cannot be ruled out, given the ecological nature of the data . The current situation necessitates a multi-pronged approach, encompassing expanded access to substance use disorder treatment, undisrupted access to harm reduction services, emphasis on risk reduction strategies, provision of a safe drug supply and decriminalization of drug use.
Availability of data and materials
All data generated or analysed during this study are included in this article and the additional files.
Novel Coronavirus Disease
Preferred Reporting Items for Systematic Reviews and Meta-Analyses
People Who Use Drugs
Severe Acute Respiratory Syndrome Coronavirus
Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727–33. https://doi.org/10.1056/NEJMoa2001017.
World Health Organization. WHO coronavirus disease (COVID-19) dashboard. Geneva, Switzerland: World Health Organization; 2020. Available from: https://covid19.who.int/
Tuite AR, Fisman DN, Greer AL. Mathematical modelling of COVID-19 transmission and mitigation strategies in the population of Ontario. Canada CMAJ. 2020;192(19):E497–505. https://doi.org/10.1503/cmaj.200476.
Holmes EA, O'Connor RC, Perry VH, Tracey I, Wessely S, Arseneault L, et al. Multidisciplinary research priorities for the COVID-19 pandemic: a call for action for mental health science. Lancet Psychiatry. 2020;7(6):547–60. https://doi.org/10.1016/S2215-0366(20)30168-1.
Imtiaz S, Shield KD, Fischer B, Elton-Marshall T, Sornpaisarn B, Probst C, et al. Recent changes in trends of opioid overdose deaths in North America. Subst Abuse Treat Prev Policy. 2020;15(1):66. https://doi.org/10.1186/s13011-020-00308-z.
Imtiaz S, Shield KD, Fischer B, Rehm J. Harms of prescription opioid use in the United States. Subst Abuse Treat Prev Policy. 2014;9(1):43. https://doi.org/10.1186/1747-597X-9-43.
Zolopa C, Hoj S, Bruneau J, Meeson JS, Minoyan N, Raynault MF, et al. A rapid review of the impacts of "big events" on risks, harms, and service delivery among people who use drugs: implications for responding to COVID-19. Int J Drug Policy. 2021;103127:103127. https://doi.org/10.1016/j.drugpo.2021.103127.
Canadian Centre on Substance Use and Addiction. CCENDU Alert: Changes Related to COVID-19 in the Illegal Drug Supply and Access to Services, and Resulting Health Harms. Ottawa, Ontario: Canadian Centre on Substance Use and Addiction; 2020.
Ali F, Russell C, Nafeh F, Rehm J, LeBlanc S, Elton-Marshall T. Changes in substance supply and use characteristics among people who use drugs (PWUD) during the COVID-19 global pandemic: a national qualitative assessment in Canada. Int J Drug Policy. 2021;103237:103237. https://doi.org/10.1016/j.drugpo.2021.103237.
Russell C, Ali F, Nafeh F, Rehm J, LeBlanc S, Elton-Marshall T. Identifying the impacts of the COVID-19 pandemic on service access for people who use drugs (PWUD): a National Qualitative Study. J Subst Abus Treat. 2021;129:108374. https://doi.org/10.1016/j.jsat.2021.108374.
Holland KM, Jones C, Vivolo-Kantor AM, Idaikkadar N, Zwald M, Hoots B, et al. Trends in US emergency department visits for mental health, overdose, and violence outcomes before and during the COVID-19 pandemic. JAMA Psychiatry. 2021;78(4):372–9. https://doi.org/10.1001/jamapsychiatry.2020.4402.
Friedman J, Beletsky L, Schriger DL. Overdose-related cardiac arrests observed by emergency medical services during the US COVID-19 epidemic. JAMA Psychiatry. 2020;78(5):562. https://doi.org/10.1001/jamapsychiatry.2020.4218.
Ontario Agency for Health Protection and Promotion (Public Health Ontario). Rapid review: Substance use-related harms and risk factors during periods of disruption. Toronto, Ontario: Queen's Printer for Ontario; 2020.
National Collaborating Centre for Methods and Tools. What is the effect of the COVID-19 pandemic on opioid and substance use and related harms? Hamilton, Ontario: National Collaborating Centre for Methods and Tools; 2020.
Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097. https://doi.org/10.1371/journal.pmed.1000097.
American medical association. Issue brief: reports of increases in opioid- and other drug-related overdose and other concerns during COVID pandemic. Updated October 31, 2020. Chicago, Illinois: American Medical Association; 2020.
Addiction. Bibliography on COVID-19 and Addiction. In: London. United Kingdom: Addiction; 8 November, 2020. p. 2020. Available from: https://www.addictionjournal.org/posts/bibliography-on-covid-19-and-addiction.
Xiao Y, Watson M. Guidance on conducting a systematic literature review. J Plan Educ Res. 2019;39(1):93–112. https://doi.org/10.1177/0739456X17723971.
British Columbia Coroners Service. Illicit drug toxicity deaths in BC January 1, 2010 – November 30, 2020. Burnaby, British Columbia: British Columbia Coroners Service; 2020.
Carolina Center for Health Informatics. Opioid dashboards and data. Chapel Hill, North Carolina: University of North Carolina; 2020. Available from: http://cchi.web.unc.edu/opioid-dashboards/
Slavova S, Rock P, Bush HM, Quesinberry D, Walsh SL. Signal of increased opioid overdose during COVID-19 from emergency medical services data. Drug Alcohol Depend. 2020;214:108176. https://doi.org/10.1016/j.drugalcdep.2020.108176.
Rodda LN, West KL, LeSaint KT. Opioid overdose-related emergency department visits and accidental deaths during the COVID-19 pandemic. J Urban Health. 2020;97(6):808–13. https://doi.org/10.1007/s11524-020-00486-y.
Glober N, Mohler G, Huynh P, Arkins T, O'Donnell D, Carter J, et al. Impact of COVID-19 pandemic on drug overdoses in Indianapolis. J Urban Health. 2020;97(6):802–7. https://doi.org/10.1007/s11524-020-00484-0.
System for Opioid Overdose Surveillance. Change in Michigan overdoses during the COVID-19 pandemic. Ann Arbor, Michigan: University of Michigan; 2020.
Alter A, Yeager C. The consequences of COVID-19 on the overdose epidemic: overdoses are increasing. Overdose Detection Mapping Application Program: Washington, District of Columbia; 2020.
Ontario Drug Policy Research Network, Office of the Chief Coroner for Ontario and Ontario Forensic Pathology Service, Public Health Ontario, Centre on Drug Policy Evaluation. In: Preliminary Patterns in Circumstances Surrounding Opioid-Related Deaths in Ontario during the COVID-19 Pandemic. Toronto, Ontario: Ontario Drug Policy Research Network; 2020.
Georgia Department of Public Health. Updated suspected drug overdose increases in Georgia amid COVID-19 Atlanta. Georgia: Georgia Department of Public Health; 2020.
Giesel S, DeLaquil M, Wright N. Drug overdose deaths among Minnesota residents from January through June 2020: drug overdose deaths during the emerging COVID-19 pandemic. Minnesota Department of Health: Saint Paul, Minnesota; 2020.
Centers for Disease Control and Prevention Health Alert Network. In: Increase in fatal drug overdoses across the United States driven by synthetic opioids before and during the COVID-19 pandemic. Atlanta, Georgia: Centers for Disease Control and Prevention; 2020.
Khatri UG, Pizzicato LN, Viner K, Bobyock E, Sun M, Meisel ZF, et al. Racial/ethnic disparities in unintentional fatal and nonfatal emergency medical services-attended opioid overdoses during the COVID-19 pandemic in Philadelphia. JAMA Netw Open. 2021;4(1):e2034878. https://doi.org/10.1001/jamanetworkopen.2020.34878.
Wang L, Weiss J, Ryan EB, Waldman J, Rubin S, Griffin JL. Telemedicine increases access to buprenorphine initiation during the COVID-19 pandemic. J Subst Abus Treat. 2021;124:108272. https://doi.org/10.1016/j.jsat.2020.108272.
Harris M, Johnson S, Mackin S, Saitz R, Walley AY, Taylor JL. Low barrier tele-buprenorphine in the time of COVID-19: a case report. J Addict Med. 2020;14(4):e136–e8. https://doi.org/10.1097/ADM.0000000000000682.
Fischer B, O'Keefe-Markman C, Lee AM, Daldegan-Bueno D. 'Resurgent', 'twin' or 'silent' epidemic? A select data overview and observations on increasing psycho-stimulant use and harms in North America. Subst Abuse Treat Prev Policy. 2021;16, 17(1).
Jones CM, Bekheet F, Park JN, Alexander GC. The evolving overdose epidemic: synthetic opioids and rising stimulant-related harms. Epidemiol Rev. 2020;42(1):154–66. https://doi.org/10.1093/epirev/mxaa011.
Degenhardt L, Grebely J, Stone J, Hickman M, Vickerman P, Marshall BDL, et al. Global patterns of opioid use and dependence: harms to populations, interventions, and future action. Lancet. 2019;394(10208):1560–79. https://doi.org/10.1016/S0140-6736(19)32229-9.
Potier C, Laprevote V, Dubois-Arber F, Cottencin O, Rolland B. Supervised injection services: what has been demonstrated? A systematic literature review. Drug Alcohol Depend. 2014;145:48–68. https://doi.org/10.1016/j.drugalcdep.2014.10.012.
Maghsoudi N, Tanguay J, Scarfone K, Rammohan I, Ziegler C, Werb D, et al. Drug checking Services for People who use Drugs: a systematic review. Addiction. 2021. https://doi.org/10.1111/add.15734.
Perri M, Kaminski N, Bonn M, Kolla G, Guta A, Bayoumi AM, et al. A qualitative study on overdose response in the era of COVID-19 and beyond: how to spot someone so they never have to use alone. Harm Reduct J. 2021;18(1):85. https://doi.org/10.1186/s12954-021-00530-3.
Perri M, Guta A, Gagnon M, Bonn M, Leece P, Bayoumi AM, et al. Developing a digital health strategy for people who use drugs: lessons from COVID-19. Digit Health. 2021;7:20552076211028404. https://doi.org/10.1177/20552076211028404.
Smart R, Pardo B, Davis CS. Systematic review of the emerging literature on the effectiveness of naloxone access laws in the United States. Addiction. 2021;116(1):6–17. https://doi.org/10.1111/add.15163.
Bonn M, Palayew A, Bartlett S, Brothers TD, Touesnard N, Tyndall M. Addressing the Syndemic of HIV, hepatitis C, overdose, and COVID-19 among people who use drugs: The potential roles for decriminalization and safe supply. J Stud Alcohol Drugs. 2020;81(5):556–60. https://doi.org/10.15288/jsad.2020.81.556.
Ivsins A, Boyd J, Beletsky L, McNeil R. Tackling the overdose crisis: The role of safe supply. Int J Drug Policy. 2020;80:102769. https://doi.org/10.1016/j.drugpo.2020.102769.
The LH. The time to end the war on drugs is long overdue. Lancet HIV. 2021;8(7):e387. https://doi.org/10.1016/S2352-3018(21)00130-2.
The Lancet HIV. The war on drugs is incompatible with the fight against HIV. The Lancet HIV. 2019;6(5):e269. https://doi.org/10.1016/S2352-3018(19)30112-2.
Barocas JA. Business not as usual - Covid-19 vaccination in persons with substance use disorders. N Engl J Med. 2021;384(2):e6. https://doi.org/10.1056/NEJMpv2035709.
Wang QQ, Kaelber DC, Xu R, Volkow ND. COVID-19 risk and outcomes in patients with substance use disorders: analyses from electronic health records in the United States. Mol Psychiatry. 2021;26(1):30–9. https://doi.org/10.1038/s41380-020-00880-7.
Ornell F, Moura HF, Scherer JN, Pechansky F, Kessler FHP, von Diemen L. The COVID-19 pandemic and its impact on substance use: implications for prevention and treatment. Psychiatry Res. 2020;289:113096. https://doi.org/10.1016/j.psychres.2020.113096.
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–62. https://doi.org/10.1016/S0140-6736(20)30566-3.
European Monitoring Centre for Drugs and Drug Addiction. EMCDDA update on the implications of COVID-19 for people who use drugs (PWUD) and drug service providers. Lisbon, Portugal: European Monitoring Centre for Drugs and Drug Addiction; 2020.
Tsai J, Wilson M. COVID-19: a potential public health problem for homeless populations. Lancet Public Health. 2020;5(4):e186–e7. https://doi.org/10.1016/S2468-2667(20)30053-0.
Armitage R, Nellums LB. Substance misuse during COVID-19: protecting people who use drugs. Public Health. 2020;183:63. https://doi.org/10.1016/j.puhe.2020.05.010.
Shadish WR, Cook TD, Campbell DT. Experimental and quasi-experimental designs for generalized causal inference. Houghton Mifflin Company: Boston, Massachusetts; 2002.
Georgia Department of Public Health. Opioid overdose surveillance preliminary report Georgia, 2019. Atlanta, Georgia: Georgia Department of Public Health; 2020.
The authors acknowledge support from the Quebec Node of the Canadian Research Initiative on Substance Misuse in the procurement of drug overdose-related deaths data from Quebec.
This research did not receive any specific grant from funding agencies in the public, commercial or not-for-profit sectors. The authors acknowledge funding from the Canadian Institutes of Health Research’s Institute of Neurosciences, Mental Health and Addiction (Canadian Research Initiative on Substance Misuse Ontario Node Grant [CUG-171602]). The funders had no role in study design, data collection, analysis and interpretation, writing of the manuscript or decision to submit the manuscript for publication.
Ethics approval and consent to participate
Research ethics approval and consent for participation were not required, as aggregate data were extracted from publicly available sources.
Consent for publication
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Additional File 1.
Provides further details on the methodology and additional tables and figures to support the results pertaining to the systematic review reported in the main text of the manuscript
Additional File 2.
Provides further details on the data to support the results pertaining to the percentage change analyses reported in the main text of the manuscript
Additional File 3.
Provides data to support the results pertaining to the percentage change analyses reported in the main text of the manuscript
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Imtiaz, S., Nafeh, F., Russell, C. et al. The impact of the novel coronavirus disease (COVID-19) pandemic on drug overdose-related deaths in the United States and Canada: a systematic review of observational studies and analysis of public health surveillance data. Subst Abuse Treat Prev Policy 16, 87 (2021). https://doi.org/10.1186/s13011-021-00423-5
- North America
- United States
- Drug overdose